Amgen's Repatha Gets NHS Nod, Sanofi's Praluent Misses Out
This article was originally published in Scrip
Executive Summary
Amgen Inc. looks to be in with a chance to push back its biggest rival, partners Sanofi and Regeneron Pharmaceuticals, and strive for dominance of the PCKS9 market space in the UK for patients with high cholesterol.